Gossamer Bio (GOSS) Free Cash Flow (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Free Cash Flow of -$38.7 million for Q1 2026, up 2.59% year-over-year from -$37.7 million in Q1 2025, and up 19.86% quarter-over-quarter from -$48.3 million in Q4 2025.
Gossamer Bio (GOSS) Free Cash Flow (2018 - 2026) Analysis & Trends
Gossamer Bio's Free Cash Flow history runs 9 years deep, the most recent figure standing at -$38.7 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 2.59% year-over-year to -$38.7 million; the TTM figure through Mar 2026 stood at -$170.3 million (down 1974.9% YoY), while the FY2025 annual figure was -$171.3 million, down 4840.74% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$38.7 million, up from -$48.3 million in the prior quarter.
- The five-year high for Free Cash Flow was $116.3 million in Q2 2024, with the low at -$53.6 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$38.7 million (2026), against an average of -$32.9 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 404.17% in 2024, then plunged 140.49% in 2025.
- Gossamer Bio's Free Cash Flow stood at -$47.5 million in 2022, then rose by 29.64% to -$33.4 million in 2023, then decreased by 6.15% to -$35.5 million in 2024, then sank by 36.17% to -$48.3 million in 2025, then increased by 19.86% to -$38.7 million in 2026.
- Business Quant data shows GOSS's Free Cash Flow at -$38.7 million in Q1 2026, -$48.3 million in Q4 2025, and -$36.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | -39.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.42 Mn |
| Jun 30, 2026 | -39.42 Mn |
| Mar 31, 2026 | -38.72 Mn |
| Mar 31, 2026 | -38.72 Mn |
| Dec 31, 2025 | -48.31 Mn |
| Dec 31, 2025 | -48.31 Mn |
| Sep 30, 2025 | -36.17 Mn |
| Sep 30, 2025 | -36.17 Mn |
| Jun 30, 2025 | -47.11 Mn |
| Jun 30, 2025 | -47.11 Mn |
| Mar 31, 2025 | -39.75 Mn |
| Mar 31, 2025 | -39.75 Mn |
| Dec 31, 2024 | -35.48 Mn |
| Dec 31, 2024 | -35.48 Mn |
| Sep 30, 2024 | -32.03 Mn |
| Sep 30, 2024 | -32.03 Mn |
| Jun 30, 2024 | 116.35 Mn |
| Jun 30, 2024 | 116.35 Mn |
| Mar 31, 2024 | -52.30 Mn |
| Mar 31, 2024 | -52.30 Mn |